New combination malaria treatment equally effective

April 5, 2012
New combination malaria treatment equally effective

(HealthDay) -- Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection, according to a study published in the April 5 issue of the New England Journal of Medicine.

Ronnatrai Rueangweerayut, M.D., from Mae Sot General Hospital in Tak, Thailand, and colleagues randomly assigned 1,271 patients from Asia or Africa (3 to 60 years old) with confirmed uncomplicated Plasmodium falciparum (P. falciparum) malaria to a fixed-dose combination of 180 mg pyronaridine plus 60 mg artesunate (848 patients) or 250 mg mefloquine plus 100 mg artesunate (423 patients) once daily for three days.

Based on the end point of adequate clinical and parasitological response on day 28, corrected for reinfection, in the per-protocol population, the researchers found that efficacy was similar for the two groups, at 99.2 percent in the pyronaridine-artesunate group and 97.8 percent for the mefloquine plus artesunate group. In the intention-to-treat population, efficacy on day 42 was 83.1 percent in the pyronaridine-artesunate group and 83.9 percent in the mefloquine plus artesunate group. Among the 211 Cambodian patients, median parasite clearance times were significantly longer in both groups.

"Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria," Rueangweerayut and colleagues conclude. "In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin."

The study was supported by a public-private partnership between Shin Poong Pharmaceutical Company and Medicines for Malaria Venture; several authors disclosed financial ties to the latter.

Explore further: Pyramax receives positive opinion from the EMA

More information: Full Text (subscription or payment may be required)

Related Stories

Pyramax receives positive opinion from the EMA

February 21, 2012

Pyramax, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day ...

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.